Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115642) titled 'Phase III Trial of Adjuvant Radiotherapy in Combination with Sintilimab versus Adjuvant TACE for Hepatocellular Carcinoma with Postoperative Narrow Margin' on Dec. 29, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences
Condition:
Hepatocellular Carcinoma
Intervention:
treatment group:Radiotherapy plus Sintilimab
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-01-01
Target Sample Size: treatment group:143;Control group:143;
Countries of Recruitment:
China
To know more, visit https://www.chict...